



COVID-19 Outpatient therapeutics update| December 31, 2021

https://drive.google.com/file/d/1Quugb176tRPnrMMIU6SAnv7RI4bJUV3_/view?usp=sharing

Slides on Tx

COVID-19 Outpatient Therapeutics - Use and Distribution Information							
Type	Name	Indication ¹			Formulation ¹	Pediatric Use	Distribution/Access Note that all state-distributed therapeutics are currently available in limited quantities
		PEP	Treatment	PEP			
monoclonal antibody	bamlanivimab/ etesevimab		✓	✓	IV	All ages	<ul style="list-style-type: none"> Available in limited quantities Providers can request through REDCap² Due to lack of effectiveness against omicron, may no longer be available soon
	casirivimab/ imdevimab (REGN-COV2)		✓	✓	IV, SQ	≥12 years ≥40 kg	<ul style="list-style-type: none"> Available in limited quantities Providers can request through REDCap² Due to lack of effectiveness against omicron, may no longer be available soon
	sotrovimab		✓		IV	≥12 years ≥40 kg	<ul style="list-style-type: none"> Distributed by CDPIE; allocation numbers determined by region Providers can request through REDCap² Provider enrollment: cdphe.comentsooper@state.oh.us
	Evusheld (tixagevimab/ cilgavimab)	✓			IM	≥12 years ≥40 kg	<ul style="list-style-type: none"> Distributed by CDPIE Ordering through Tiberius³ Ordering started with transplant centers; now expanding to other hospitals/healthcare systems
antiviral	molnupiravir		✓		PO	none	<ul style="list-style-type: none"> Distributed by CDPIE allocations currently being delivered to hospitals/health systems and HSA sites Ordering requests through HPOP⁴
	Paxlovid (nirmatrelvir/ ritonavir)		✓		PO	≥12 years ≥40 kg	<ul style="list-style-type: none"> Ordering requests through HPOP⁴
	remdesivir ⁵		✓		IV	≥12 years ≥40 kg	Not distributed by CDPIE

¹PEP = pre-exposure prophylaxis; PEP = post-exposure prophylaxis

¹IV = intravenous; SQ = subcutaneous; IM = intramuscular; PO = oral

²REDCap order form: https://cdphe.redcap.state.oh.us/survey/13-1_09/8E8J0LE40H00; regional allocation will determine availability

³<https://protect.cwis.hhs.gov/mvd/pats/login/>

⁴<https://hps.oracle.com/en/industries/health-sciences/vpop-provider/vpopu/get-started-oracle-vpop-provider-per-141326>

⁵FDA approved for inpatient use; outpatient use is an off-label indication